Emcure Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	96,835	92,035	78,960	66,583	59,858	58,554
Revenue Growth	18.36%	16.56%	18.59%	11.23%	2.23%	16.33%
Cost of Revenue	39,282	37,473	32,225	25,357	23,185	22,864
Gross Profit	57,552	54,562	46,735	41,225	36,673	35,690
Selling, General & Admin	15,682	18,861	17,264	15,577	13,069	11,805
Other Operating Expenses	22,943	17,813	14,782	13,351	11,597	10,562
Operating Expenses	42,876	40,824	35,887	32,052	27,459	24,835
Operating Income	14,676	13,738	10,847	9,173	9,214	10,855
Interest Expense	-1,485	-1,065	-1,249	-1,949	-1,849	-1,470
Interest & Investment Income	-	16.83	90.44	207.59	118.34	101.97
Currency Exchange Gain (Loss)	1,288	1,188	2.8	48.12	190.15	367.78
Other Non Operating Income (Expenses)	110.39	-276.95	-314.36	-205.93	-137.55	-124.92
EBT Excluding Unusual Items	14,590	13,601	9,377	7,274	7,536	9,730
Gain (Loss) on Sale of Investments	-	15.24	58.04	25.32	1.21	-
Gain (Loss) on Sale of Assets	-	-2.34	382.35	71.92	-3.33	-4.08
Legal Settlements	-	-35	-82.9	-	-	-
Other Unusual Items	-691.07	-707.13	-20.88	-99.31	-61.46	-
Pretax Income	13,899	12,871	9,713	7,272	7,472	9,725
Income Tax Expense	3,709	3,459	2,639	1,997	1,854	2,700
Earnings From Continuing Operations	10,190	9,413	7,075	5,276	5,618	7,026
Net Income to Company	10,190	9,413	7,075	5,276	5,618	7,026
Minority Interest in Earnings	-75.81	-169.08	-261.35	-293.92	-298.26	-403.56
Net Income	10,114	9,244	6,813	4,982	5,320	6,622
Net Income to Common	10,114	9,244	6,813	4,982	5,320	6,622
Net Income Growth	35.90%	35.67%	36.76%	-6.36%	-19.66%	68.86%
Shares Outstanding (Basic)	190	190	187	181	181	181
Shares Outstanding (Diluted)	190	190	187	181	181	181
Shares Change	0.24%	1.33%	3.41%	0.01%	-	-
EPS (Basic)	53.35	48.77	36.43	27.54	29.42	36.62
EPS (Diluted)	53.35	48.77	36.43	27.54	29.42	36.62
EPS Growth	35.57%	33.88%	32.27%	-6.38%	-19.66%	68.90%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	5,830	6,299	8,215	3,563	3,900
Free Cash Flow Per Share	-	30.76	33.68	45.42	19.70	21.57
Dividend Per Share	-	3.600	3.000	-	2.000	3.000
Dividend Growth	-	20.00%	-	-	-33.33%	200.00%
Gross Margin	59.43%	59.28%	59.19%	61.92%	61.27%	60.95%
Operating Margin	15.16%	14.93%	13.74%	13.78%	15.39%	18.54%
Profit Margin	10.45%	10.04%	8.63%	7.48%	8.89%	11.31%
Free Cash Flow Margin	-	6.33%	7.98%	12.34%	5.95%	6.66%
EBITDA	19,046	17,229	14,121	11,805	11,446	12,911
EBITDA Margin	19.67%	18.72%	17.88%	17.73%	19.12%	22.05%
D&A For EBITDA	4,370	3,491	3,274	2,632	2,232	2,057
EBIT	14,676	13,738	10,847	9,173	9,214	10,855
EBIT Margin	15.16%	14.93%	13.74%	13.78%	15.39%	18.54%
Effective Tax Rate	26.69%	26.87%	27.17%	27.45%	24.81%	27.76%
Revenue as Reported	96,945	92,162	79,633	67,021	60,317	59,189
Advertising Expenses	-	3,258	2,734	2,585	1,828	1,633